Welcome to Journal of Clinical Pathway’s new case report exploration. This interactive case report will engage your experience and knowledge about the details of a given case. Along the way, we will provide details and at the end, we will share the patient’s outcome. READ MORE

News

According to a recent study, treatment with the multikinase inhibitor entrectinib produces durable responses in all of the following soft-tissue sarcomas EXCEPT...

READ MORE

A recent study compared the effects of laser-assisted resection with pulmonary metastasectomy in patients with extrathoracic sarcoma.

READ MORE

Patients with soft tissue sarcoma experienced a confirmed clinical response following treatment with a targeted therapy, according to a recent study.

READ MORE

Young patients with head and neck sarcoma treated with proton beam therapy had similar outcomes with less of an impact on quality of life as those treated with traditional photon radiation.

READ MORE

Interactive Features

Welcome to Journal of Clinical Pathway’s new case report exploration. This interactive case report will engage your experience and knowledge about the details of a given case. Along the way, we will provide details and at the end, we will share the patient’s outcome.

READ MORE

Research in Review

Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors, supporting efforts for further research.

READ MORE

Neoadjuvant chemotherapy with epirubicin plus ifosfamide improves outcomes in patients with soft tissue sarcoma who are at high-risk of recurrence.

READ MORE

Results argue against the inclusion of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma.

READ MORE

Resources

SEOM has published updated guidelines for the treatment of soft-tissue sarcoma, which include recommendations for referrals, imaging, biopsy, radiotherapy, and adjuvant and neoadjuvant chemotherapy.

READ MORE

Conferences

Health-related quality of life and its impact on disease progression should be a consideration when selecting treatment for sarcoma.

READ MORE